CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) In Thousands, unless otherwise specified	12 Months Ended
Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2009
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 8,461	$ 4,876	$ 2,706
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization of property, plant and equipment	1,154	1,228	1,017
Amortization of intangible assets	734	782	539
Amortization of investment premium, net	1,263	1,626	1,027
Provision for uncollectible accounts	250	204	149
Stock-based compensation	1,231	1,455	937
Tax benefit from stock option exercises	(522)	(296)	(203)
Acquired in-process research and development expense	0	0	3,500
Loss on sale of investments	0	0	1,350
Impairment of intangible assets	0	0	600
Loss on sale or disposal of property, plant and equipment	25	192	25
Deferred income taxes	(107)	(117)	(2,206)
Changes in operating assets and liabilities:
Accounts receivable	(2,811)	(1,980)	(953)
Inventories	(565)	(1,709)	62
Other current assets	(258)	40	677
Accounts payable	591	(318)	637
Accrued expenses	1,931	920	(118)
Net cash provided by operating activities	11,377	6,903	9,746
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(1,932)	(1,102)	(1,156)
Investments in identifiable intangible assets	(316)	(123)	(105)
Purchase of assets of Pegasus Biologics, Inc.	0	0	(12,319)
Purchases of investments	(51,116)	(79,397)	(43,226)
Redemptions of investments	50,228	73,618	23,405
Decrease in restricted cash	0	0	2,950
Other	0	(2)	(335)
Net cash used in investing activities	(3,136)	(7,006)	(30,786)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds related to stock-based compensation plans	3,879	1,996	823
Repurchase of the Company's common stock	(7,580)	(5,101)	(11,018)
Excess tax benefit of stock option exercises	522	296	203
Net cash used in financing activities	(3,179)	(2,809)	(9,992)
Net change in cash and cash equivalents	5,062	(2,912)	(31,032)
Cash and cash equivalents at beginning of year	12,951	15,863	46,895
Cash and cash equivalents at end of year	$ 18,013	$ 12,951	$ 15,863

Name:	us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.